Skip to main content
. 2018 Feb 1;17(4):4899–4908. doi: 10.3892/mmr.2018.8535

Figure 3.

Figure 3.

Mechanism of MTA2-mediated signaling pathways in non-small cell lung carcinoma cells. (A) E-cadherin, Snail, N-cadherin and vimentin expression levels in A549 cells following treatment with the indicated agents. (B) ERK and AKT expression in A549 cells following treatment with the indicated agents. (C) Apoptosis-associated proteins caspase-3 and Bad expression levels in A549 cells. (D) VEGFR1, VEGFR2 and VEGFR3 expression levels in AbMTA2-treated A549 cells. (E) VEGF and EGF expression levels in AbMTA2-treated A549 cells. (F) Ep-CAM and TAF expression in A549 cells. The data are presented as the mean ± standard error of the mean of three independent experiments. **P<0.01 vs. control. MTA2, metastasis associated protein MTA2; Snail, zinc-finger protein SNAI1; ERK, extracellular signal-regulated kinase; AKT, RAC-α serine/threonine protein kinase; Bad, Bcl2-associated agonist of cell death; VEGFR, vascular endothelial growth factor receptor; EGF, pro-epidermal growth factor; Ep-CAM, epithelial cell adhesion molecule; TAF, tumor angiogenesis factor; si, small interfering; Ab, antibody.